N-glycan deleted HIV-1 envelope glycoprotein trimers
AssigneesInternational AIDS Vaccine Initiative, The Scripps Research Institute
InventorsViktoriya Dubrovskaya, Francisco Javier Guenaga, Richard Wyatt
Life of this patent
Estimating the term…
Abstract
The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
Claims14
An engineered or non-naturally occurring trimer, wherein the trimer is a flexibly linked NFL2P trimer, wherein the trimer comprises one or more trimer-derived mutations (“TD mutations”), wherein said TD mutations comprise one or more mutations at residue 569 wherein a numerical position of an amino acid residue of the trimer corresponds with a numerical position of an amino acid residue of a 16055 NFL Env protein upon direct alignment of the numerical positions of the amino acid residues of the trimer with the numerical positions of the amino acid residues of the 16055 NFL Env protein, whose sequence is based on a BG505 numbering system.
An engineered or non-naturally occurring trimer, wherein the trimer is a flexibly linked NFL2P trimer, wherein the trimer comprises a N276Q/N463Q glycan-deleted variant with or without N332 restored, a +N332 N276Q/N360Q/N463Q triple N-glycan-deleted variant or a +N332 N276Q/N360Q/N463Q/N301Q quadruple N-glycan-deleted variant wherein a numerical position of an amino acid residue of the trimer corresponds with a numerical position of an amino acid residue of a 16055 NFL Env protein upon direct alignment of the numerical positions of the amino acid residues of the trimer with the numerical positions of the amino acid residues of the 16055 NFL Env protein, whose sequence is based on a BG505 numbering system.
Dependencies are inferred from the claim text.